250 related articles for article (PubMed ID: 24322994)
1. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor.
Ostheimer C; Bache M; Güttler A; Kotzsch M; Vordermark D
Strahlenther Onkol; 2014 Mar; 190(3):276-82. PubMed ID: 24322994
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
4. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer.
Ostheimer C; Bache M; Güttler A; Reese T; Vordermark D
BMC Cancer; 2014 Nov; 14():858. PubMed ID: 25416631
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
De Schutter H; Landuyt W; Verbeken E; Goethals L; Hermans R; Nuyts S
BMC Cancer; 2005 Apr; 5():42. PubMed ID: 15847702
[TBL] [Abstract][Full Text] [Related]
6. Blood serum proteins as biomarkers for prediction of survival, locoregional control and distant metastasis rate in radiotherapy and radio-chemotherapy for non-small cell lung cancer.
Suwinski R; Giglok M; Galwas-Kliber K; Idasiak A; Jochymek B; Deja R; Maslyk B; Mrochem-Kwarciak J; Butkiewicz D
BMC Cancer; 2019 May; 19(1):427. PubMed ID: 31068179
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - A survival model with external validation.
Carvalho S; Troost EG; Bons J; Menheere P; Lambin P; Oberije C
Radiother Oncol; 2016 Jun; 119(3):487-94. PubMed ID: 27139126
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
[TBL] [Abstract][Full Text] [Related]
9. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer.
Ilie M; Mazure NM; Hofman V; Ammadi RE; Ortholan C; Bonnetaud C; Havet K; Venissac N; Mograbi B; Mouroux J; Pouysségur J; Hofman P
Br J Cancer; 2010 May; 102(11):1627-35. PubMed ID: 20461082
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
Hui EP; Chan AT; Pezzella F; Turley H; To KF; Poon TC; Zee B; Mo F; Teo PM; Huang DP; Gatter KC; Johnson PJ; Harris AL
Clin Cancer Res; 2002 Aug; 8(8):2595-604. PubMed ID: 12171890
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of carbonic anhydrase IX mRNA in human non-small cell lung cancer.
Simi L; Venturini G; Malentacchi F; Gelmini S; Andreani M; Janni A; Pastorekova S; Supuran CT; Pazzagli M; Orlando C
Lung Cancer; 2006 Apr; 52(1):59-66. PubMed ID: 16513206
[TBL] [Abstract][Full Text] [Related]
12. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer.
Kim SJ; Rabbani ZN; Dewhirst MW; Vujaskovic Z; Vollmer RT; Schreiber EG; Oosterwijk E; Kelley MJ
Lung Cancer; 2005 Sep; 49(3):325-35. PubMed ID: 15935515
[TBL] [Abstract][Full Text] [Related]
13. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas.
Driessen A; Landuyt W; Pastorekova S; Moons J; Goethals L; Haustermans K; Nafteux P; Penninckx F; Geboes K; Lerut T; Ectors N
Ann Surg; 2006 Mar; 243(3):334-40. PubMed ID: 16495697
[TBL] [Abstract][Full Text] [Related]
14. [Relation between carbonic anhydrase IX serum level, hypoxia and radiation resistance of head and neck cancers].
Rosenberg V; Pastoreková S; Zaťovičová M; Slezák P; Waczulíková I; Svec J
Klin Onkol; 2014; 27(4):269-75. PubMed ID: 25115716
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters.
Kappler M; Taubert H; Holzhausen HJ; Reddemann R; Rot S; Becker A; Kuhnt T; Dellas K; Dunst J; Vordermark D; Hänsgen G; Bache M
Strahlenther Onkol; 2008 Aug; 184(8):393-9. PubMed ID: 18956515
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers.
Le QT; Chen E; Salim A; Cao H; Kong CS; Whyte R; Donington J; Cannon W; Wakelee H; Tibshirani R; Mitchell JD; Richardson D; O'Byrne KJ; Koong AC; Giaccia AJ
Clin Cancer Res; 2006 Mar; 12(5):1507-14. PubMed ID: 16533775
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer.
Swinson DE; Jones JL; Richardson D; Wykoff C; Turley H; Pastorek J; Taub N; Harris AL; O'Byrne KJ
J Clin Oncol; 2003 Feb; 21(3):473-82. PubMed ID: 12560438
[TBL] [Abstract][Full Text] [Related]
18. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Mack PC; Redman MW; Chansky K; Williamson SK; Farneth NC; Lara PN; Franklin WA; Le QT; Crowley JJ; Gandara DR;
J Clin Oncol; 2008 Oct; 26(29):4771-6. PubMed ID: 18779603
[TBL] [Abstract][Full Text] [Related]
19. High serum carbonic anhydrase IX predicts shorter survival in head and neck cancer.
Rosenberg V; Pastorekova S; Zatovicova M; Vidlickova I; Jelenska L; Slezak P
Bratisl Lek Listy; 2016; 117(4):201-4. PubMed ID: 27075382
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2 laryngeal carcinoma treated with radiotherapy.
Wachters JE; Schrijvers ML; Slagter-Menkema L; Mastik M; de Bock GH; Langendijk JA; Kluin PM; Schuuring E; van der Laan BF; van der Wal JE
Laryngoscope; 2013 Sep; 123(9):2154-60. PubMed ID: 24167820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
